BUMECAINE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H28N2O
Molecular Weight	288.4277
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCN1CCCC1C(=O)NC2=C(C)C=C(C)C=C2C

InChI

InChIKey=VEPZOLKTNZOTTQ-UHFFFAOYSA-N

InChI=1S/C18H28N2O/c1-5-6-9-20-10-7-8-16(20)18(21)19-17-14(3)11-13(2)12-15(17)4/h11-12,16H,5-10H2,1-4H3,(H,19,21)

HIDE SMILES / InChI

Molecular Formula	C18H28N2O
Molecular Weight	288.4277
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2415182 | http://www.rusmedserv.com/lekarstva/komponent/bumecaine.html | https://www.piluli.kharkov.ua/drugs/drug/899 | https://www.ncbi.nlm.nih.gov/pubmed/3764717

Bumecaine (Pyromecaine) is a local anesthetic and anti-arrhythmic drug. It is indicated as an agent for superficial anesthesia during medical and diagnostic procedures in dentistry, ophthalmology, otorhinolaryngology, surgery, bronchology, gastroenterology, urology. The experiments on the isolated neurons in the rat spinal ganglions have shown that interaction of pyromecaine with inactivated Na+ channels makes a considerable contribution to the blocking effect of anesthesia. Oral administration of pyromecaine pills considerably depresses platelet aggregation and even causes platelet disaggregation. Possible side effects are: general weakness, nausea, vomiting, headache, dizziness, fainting, a drop in blood pressure. Quinidine increases the risk of side effects.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium channels 3 Target ID: Sodium channels Sources: https://www.ncbi.nlm.nih.gov/pubmed/2415182 \| http://www.rusmedserv.com/lekarstva/komponent/bumecaine.html	Blocker 555

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 619 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3752610 https://www.ncbi.nlm.nih.gov/pubmed/3727285 https://www.ncbi.nlm.nih.gov/pubmed/6649293	Primary		Approved 8583	Bumecain Approved Use Pyromecaine is prescribed as an anesthetic for superficial anesthesia during medical and diagnostic procedures in dentistry, ophthalmology, otorhinolaryngology, surgery, bronchology, gastroenterology, urology. Pyromecaine is also used as an antiarrhythmic agent.
Arrhythmia 45 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6196040 https://www.ncbi.nlm.nih.gov/pubmed/3493714 https://www.ncbi.nlm.nih.gov/pubmed/4057729	Primary		Approved 8583	Bumecain Approved Use Pyromecaine is prescribed as an anesthetic for superficial anesthesia during medical and diagnostic procedures in dentistry, ophthalmology, otorhinolaryngology, surgery, bronchology, gastroenterology, urology. Pyromecaine is also used as an antiarrhythmic agent.

C_max

Value	Dose	Co-administered	Analyte	Population
0.61 μg/mL EXPERIMENT https://link.springer.com/article/10.1007/BF00765964	50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered:		BUMECAINE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.22 μg/mL EXPERIMENT https://link.springer.com/article/10.1007/BF00765964	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:		BUMECAINE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
34.2 μg × min/mL EXPERIMENT https://link.springer.com/article/10.1007/BF00765964	50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered:		BUMECAINE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
68.7 μg × min/mL EXPERIMENT https://link.springer.com/article/10.1007/BF00765964	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:		BUMECAINE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.3 h EXPERIMENT https://link.springer.com/article/10.1007/BF00765964	50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered:		BUMECAINE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.75 h EXPERIMENT https://link.springer.com/article/10.1007/BF00765964	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:		BUMECAINE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

PubMed

Title	Date	PubMed
[A morphological evaluation of the tissue status of the oral mucosa after anesthesia applied with dicaine and pyromecaine solutions].	1990-11-01	2087717
[The action of aqueous solutions of dicaine and pyromecaine on the epithelium of the oral mucosa].	1990-05-01	2389270
[The Ca2+ reactivity and the subunit composition of myocardial actomyosin during the pyromecaine and pyrroxan treatment of experimental ischemia].	1990-01-01	1970309
[Interaction of quinidine, lidocaine, tricaine and pyromecaine with heparin].	1989-07-01	2806526
[Effect of anti-angina therapy on phospholipid levels of the myocardium in ischemic lesions].	1988-10	3147341
[Anti-arrhythmia properties of pyromecaine].	1983-09-01	6628657

Patents

Sample Use Guides

In Vivo Use Guide

50-100 mg slowly. Prolonged therapy is given in a dose 100 mg 2-3 times with an interval between administrations of 15-20 minutes. The maximum dose is 1.5 g / day.

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:25:52 GMT 2025` Edited by `admin` on `Mon Mar 31 18:25:52 GMT 2025`
Record UNII	B77K612SPZ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BUMECAINE

Official Name

English

(±)-BUMECAINE

Preferred Name

English

BUMECAINE, (±)-

Common Name

English

bumecaine [INN]

Common Name

English

1-BUTYL-2',4',6'-TRIMETHYL-2-PYRROLIDINECARBOXANILIDE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C245